Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (SHE:300357) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (SHE:300357) has a market capitalization of $1.95 Billion (CN¥13.30 Billion) as of May 3, 2026. Listed on the SHE stock exchange, this China-based company holds position #6380 globally and #1424 in its home market, demonstrating a -4.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's stock price CN¥25.40 by its total outstanding shares 523584000 (523.58 Million). Analyse 300357 cash generation efficiency to see how efficiently the company converts income to cash.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.13 Billion to $1.95 Billion (8.02% CAGR).
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.68x
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market cap is 1.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.90x
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market cap is 4.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.13 Billion | $267.11 Million | $117.82 Million | 4.24x | 9.60x |
| 2016 | $789.86 Million | $312.09 Million | $129.20 Million | 2.53x | 6.11x |
| 2017 | $1.12 Billion | $385.58 Million | $186.10 Million | 2.90x | 6.00x |
| 2018 | $1.52 Billion | $500.74 Million | $232.88 Million | 3.04x | 6.53x |
| 2019 | $3.30 Billion | $639.35 Million | $298.30 Million | 5.16x | 11.06x |
| 2020 | $5.75 Billion | $636.21 Million | $278.45 Million | 9.03x | 20.64x |
| 2021 | $4.30 Billion | $807.69 Million | $337.99 Million | 5.33x | 12.73x |
| 2022 | $4.16 Billion | $896.02 Million | $348.77 Million | 4.64x | 11.92x |
| 2023 | $2.20 Billion | $848.19 Million | $310.18 Million | 2.59x | 7.10x |
| 2024 | $1.56 Billion | $925.39 Million | $317.82 Million | 1.68x | 4.90x |
Competitor Companies of 300357 by Market Capitalization
Companies near Zhejiang Wolwo Bio-Pharmaceutical Co Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Zhejiang Wolwo Bio-Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market cap moved from $1.13 Billion to $ 1.95 Billion, with a yearly change of 8.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.95 Billion | -10.41% |
| 2025 | CN¥2.17 Billion | +39.52% |
| 2024 | CN¥1.56 Billion | -29.27% |
| 2023 | CN¥2.20 Billion | -47.06% |
| 2022 | CN¥4.16 Billion | -3.40% |
| 2021 | CN¥4.30 Billion | -25.12% |
| 2020 | CN¥5.75 Billion | +74.28% |
| 2019 | CN¥3.30 Billion | +116.82% |
| 2018 | CN¥1.52 Billion | +36.18% |
| 2017 | CN¥1.12 Billion | +41.41% |
| 2016 | CN¥789.86 Million | -30.20% |
| 2015 | CN¥1.13 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.95 Billion USD |
| MoneyControl | $1.95 Billion USD |
| MarketWatch | $1.95 Billion USD |
| marketcap.company | $1.95 Billion USD |
| Reuters | $1.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more